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MHCThe Vaccinia virus gene A35R (Copenhagen designation) is highly conserved in mammalian-tropic
poxviruses and is an important virulence factor, but its function was unknown. We show herein that A35
does not affect viral infectivity, apoptosis induction, or replication; however, we found that A35 signiﬁcantly
inhibited MHC class II-restricted antigen presentation, immune priming of T lymphocytes, and subsequent
chemokine and cytokine synthesis. A35 localized to endosomes and reduced the amount of a model
antigenic peptide displayed in the cleft of class II MHC. In addition, A35 decreased VV speciﬁc T cell responses
in vivo. Thus, this is the ﬁrst report identifying a function for the A35 protein in virulence as well as the ﬁrst
report identifying a VV gene that inhibits peptide antigen presentation.
© 2009 Elsevier Inc. All rights reserved.Introduction
Poxviruses are large, double-stranded DNA viruses (∼200 kb) that
are capable of infecting a wide variety of animals (Moss, 2001). The
most infamous poxvirus is Variola virus, the causative agent of
smallpox. Smallpox is estimated to have killed over 500 million
people in the 20th century before it was declared eradicated by the
World Health Organization in 1980 (Mahalingam et al., 2004).
Smallpox now presents itself as a danger in biowarfare and bioterror-
ism. Other poxviruses can also cause signiﬁcant disease in humans. In
2003, a Monkeypox outbreak occurred in the United States, infecting
over 70 people (Chen et al., 2005). Fortunately, this was an attenuated
strain, and there were no human fatalities (Chen et al., 2005). A
widespread monkeypox outbreak would be more difﬁcult to contain
than smallpox, due to the fact that monkeypox can replicate and
persist in animal reservoirs. Other emerging zoonotic poxviruses
include buffalopox in Asia (Kolhapure et al., 1997), tanapox in Africa,
Europe and the United States (Dhar et al., 2004; Stich et al., 2002),
cowpox in humans and primates (causing widespread fatalities)
(Martina et al., 2006;Matz-Rensing et al., 2006; Steinborn et al., 2003),
and Cantagalo in South America (Damaso et al., 2000). Molluscum
contagiosum virus is commonly seen in children and AIDS patients,date cells; MOI, multiplicity of
hours post infection.
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(Molino et al., 2004), and is emerging as a sexually transmitted disease.
The eradication of smallpox was the result of the most successful
vaccination program in history. Routine vaccination was stopped in
most countries in the early 1970’s due to the poor safety record of the
vaccine, live Vaccinia virus (VV). Vaccination is contraindicated for
many individuals, including those who have inﬂammatory skin
conditions, such as eczema, and those that are immunocompromised
or pregnant (Lederman et al., 2009). In a recent vaccine trial, it was
reported that 1 out of every 450 of those vaccinated had a serious
adverse vaccine reaction (Casey et al., 2005), and vaccine trials were
stopped after reports of increased adverse cardiac events following
vaccination (Eckart et al., 2004; Upfal and Cinti, 2004). In recent years,
attenuated and/or non-replicating VV strains have been increasingly
employed to reduce risks, and many VV strains are being used as a
platform in the development of vaccines for other diseases, such as
HIV, malaria, and cancer (Dunachie et al., 2006; Schell et al., 2009;
Stober et al., 2007; Viner et al., 2006). Thus it is crucial to elucidate the
virulence mechanisms in VV and particularly those that interfere with
the development of a robust immune response. An increased
understanding of poxvirus pathogenesis will aid both in antiviral
drug development and in the design of improved vaccines.
While VV elicits a strong immune response, it also encodes a
plethora of immunosuppressive genes andmany of unknown function
(Upton et al., 2003a). Gene 158 of Vaccinia virus Western Reserve
(WR) strain, commonly referred to as the A35 gene by the VV
Copenhagen designation, is highly conserved in mammalian-tropic
poxviruses and vaccine strains (Roper, 2006; Upton et al., 2003b), but
has no similarity to non-poxvirus proteins, giving no clues as to its
Fig. 1. A35 inhibits the amount of antigen presentation-induced IL-2 and NO. PEC were
isolated from a rat, infected with VV (MOI=2) for 5 h, pulsed for 30 min with 50 nM
GPMBP, and then incubated with the cognate CD4+ RsL.11 T cell line. Uninfected PEC
served as a control. At 24- to 48-hpi, supernatants (50 μl) were collected and assayed
for either IL-2 using the IL-2 dependent cell line CTLL (A) or for NO using Greiss reagent
(B). For the CTLL bioassay, media only was used to deﬁne the background control level
and known IL-2 containing supernatants were used as positive control. IL-2 production
was determined as the mean OD value of the experimental group minus the
background control level. ⁎ pb0.05.
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several tissue culture cell lines, but was highly attenuated (100–1000
fold) in the intranasal and intraperitoneal mouse challenge models
(Roper, 2006; Rehm et al., 2010). A rescue virus was constructed that
returned the wild type A35 gene to the mutant, and this virus
construct restored virulence, conﬁrming that the viral phenotype
mapped to the A35 locus. While it is difﬁcult to compare the virulence
of various gene deletion mutants because many have not been tested
in the intranasal model measuring weight loss (intracranial inocula-
tions or measures of viral titers in organs have often been performed
instead), available data in the i.n. model indicate that the A35Δ virus is
more attenuated than the A46R deletion mutant (Stack et al., 2005),
similar in virulence to the IL-18 binding protein knock out virus
(Reading and Smith, 2003), slightly less attenuated than the TK
knockout (Lee et al., 1992) and less attenuated than the E3L deletion,
which causes a 1000-fold attenuation (Vijaysri et al., 2008). The A35Δ
virus produced similar quantities of the variousmorphogenic forms of
virus compared to the parental wild type WR virus, with similar
kinetics, and virus particles were similarly infectious on a per particle
basis (Roper, 2006). We showed that this gene encodes a non-
glycosylated, non-secreted 23 kDa protein expressed early during the
virus life cycle, but its mechanism of action was unknown. Here, we
show that VV A35 gene product blocks immune priming of T
lymphocytes by interfering with MHC class II-restricted antigen
presentation.
Results
A35 effects on replication
We have shown previously that the A35Δ virus is attenuated in a
mouse challenge model but that the mutant virus replicated and
spread similar to the WR parental strain in eight cell lines (RK-13,
HeLa, CV-1, BS-C-1, A549, MRC-5, TK-, BHK-21) derived from human,
rabbit, monkey and hamster (Roper, 2006). Still it was possible that
the A35Δ was attenuated in vivo because the A35 gene was required
for replication in certain cell types or tissues, such as immune cells,
neural tissue (since the VV-WR strain is neurovirulent) (Smee and
Sidwell, 2004), or heart because VV causes cardiac inﬂammation
(Arness et al., 2004; Eckart et al., 2004). Various cell preparations
listed below (or BS-C-1 cells as control permissive cells) (Roper, 2006)
were infected with WR or A35Δmutant at an MOI of 1 for 1 day, and
then virus titers were measured. The presence of the A35 gene in WR
did not reproducibly enhance viral replication more than 2-fold
relative to the A35Δ in any of the cells or tissues tested, including:
Lewis Rat Peritoneal Exudate Cells (PEC), splenocytes from a young
and old rat, rat thymocytes, activated and resting RSL-11 T cells, R1-T
T cells, rat alveolar Macrophage line NR8383, mouse CTLL, PC-12
neuronal cells (NGF-differentiated and undifferentiated morpholo-
gies), Heldtilt Mouse primary brain and heart cell suspensions, human
fetal ﬁbroblasts, and HEK (human kidney line) cells (data not shown).
We also assessed the effects of A35 on early replication in tissues of
mice intranasally challenged with WR and A35Δ at 104 pfu/mouse
(Roper, 2006) and found no signiﬁcant difference in replication in
nose, lungs, blood, brain and spleen on days 1, 2 and 3 post challenge.
Thus, there was no evidence for A35 involvement in host range or
tissue tropism, suggesting that A35 is not required for any steps in
replication, morphogenesis, or spread of virus.
A35 inhibits IL-2 and NO production
Because the A35 gene was not required for replication but did
affect virulence in vivo, we suspected that A35 might be involved in
regulating aspects of the host immune response. To test this
hypothesis, we used a model in vitro MHC class II-restricted antigen
presentation system (Mannie and Norris, 2001) and measuredresponses of both the T lymphocytes and the macrophage APC. Rats are
naturally infected with orthopoxviruses (Martina et al., 2006), and rat
peritoneal exudate cells (PEC) are a rich source of normal primary
macrophage. PEC were infected in triplicate with WR virus or the A35Δ
virus, pulsed with antigen (guinea pigmyelin basic protein, GPMBP), and
incubated in varying numbers with a cognate CD4+ T cell line, RsL.11
(Mannie and Norris, 2001). Supernatants were collected, and IL-2
production was determined as a measure of the T cell response to the
antigen presentation. T cells in the uninfected groupswere able to secrete
more IL-2 than either the T cells in the A35Δ-infected or theWR-infected
groups (Fig. 1A). The WR-infected PECs caused the T cells to secrete
signiﬁcantly (pb0.05) less IL-2 than A35Δ-infected cells 15–72 hpi,
indicating that A35 down-regulates MHC class II-restricted antigen
presentation responses in vitro. A similar A35-mediated down-regulation
of IL-2productionwasobservedwhen restingPECs andunfractionated rat
splenocytes were used as APC (data not shown). No IL-2was produced in
the absence of antigen or either cell type indicating that IL-2 production is
a speciﬁc response to antigen presentation.
Since production of IL-2 is a measure of the T cell response, we also
wanted to measure nitric oxide (NO), which is produced by the
macrophage and has been shown to be an important anti-viral
defense (Karupiah et al., 1993; MacMicking et al., 1997). NO
production was measured in supernatants collected from the in
vitro antigen presentation system described above. Upon antigen
presentation stimulation, uninfected macrophages produced signiﬁ-
cantly more NO than infected cells, while WR-infected macrophages
produced signiﬁcantly (pb0.05) less NO than the A35Δ-infected
macrophages (Fig. 1B). NOwas not produced in the absence of antigen
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response. These data indicate that A35 inhibits both the T lymphocyte
and APC responses to antigen presentation.
A35 reduces cytokine responses induced by antigen presentation
We next wanted to determine whether A35 speciﬁcally reduced
the amount of IL-2 and NO produced as the result of antigen
presentation (Fig. 1) or if the presence of A35 in WR broadly affected
cytokine responses. Similar to experiments above, PEC were infected
in triplicate with WR or A35Δ, pulsed with antigen, and added to
RsL.11 T cells. Supernatant cytokines were measured using an
antibody-bead-based ﬂuorescent assay. Results showed a broad and
signiﬁcant reduction in multiple cytokines and chemokines (Fig. 2).
The A35Δ virus evoked signiﬁcantly (pb0.05) higher levels of MIP1α,
IL-1β, GMCSF, IL-1α, IL-2 (conﬁrming our previous IL-2 bioassay
results), IFN-α, 1L-17, GROKC, RANTES, and TNFα, (but not IL-18)
than WR, suggesting that the presence of A35 inhibits production of
these cytokines and chemokines and generally dampens all antigen
presentation-induced responses.
A35 does not affect the RsL.11 or CTLL T cells directly
In the antigen presentation experiments described above, PEC
were pre-infected prior to addition of antigen or T cells. However, it
remained possible that the T cells also became infected during the
co-incubation, as some T cells can be infected by VV (Chahroudi et
al., 2005; Sanchez-Puig et al., 2004). To determine if VV and A35 had
any direct effects on the responding T cells, we performed a similar
assay but with infected T cells and uninfected PEC. We determined if
VV and A35 affected the ability of the RsL.11 T cell to produce IL-2.
RsL.11 T cells were incubated with either WR or A35Δ for 3 h,
washed, and then incubated with a titration of uninfected antigen-
pulsed PEC. Supernatants were harvested 24–48 hpi, similar to
experiments in Figs. 1 and 2, and tested for IL-2. Infection with
either virus did not signiﬁcantly affect the response of the T cell
compared to uninfected T cells (Fig. 3A). We also found that VV did
not affect RsL.11 responses to mitogen (ConA) or chemical
stimulation (PMA/ionomycin) (Fig. 3B).Fig. 2. A35 globally reduces antigen presentation-induced cytokine synthesis by APC and T c
5 h, pulsed with 50 nM GPMBP, and then co-cultured with the cognate CD4+ RsL.11 T cel
production of cytokines using the LincoPlex 24 Rat Cytokine/Chemokine Luminex Bead Imm
scale. IL-6, IL-18, and MCP-1 were not signiﬁcantly reduced by the presence of the A35 genWe next wanted to assess whether RsL.11 T cells were permissive
to VV infection.We incubated VV with the known permissive cell line,
BS-C-1, and RsL.11 T cells. Levels of infectious virus increased 2 logs in
the BS-C-1 culture but did not increase in the RsL.11 T cell culture
(data not shown), and infection had no signiﬁcant effect on cellular
metabolism up to 64 hpi (Fig. 3C). Together these data indicate that
the RsL.11 T cells are refractory to VV infection.
To assess viral affects on the CTLL cells used in the IL-2 bioassay,
CTLL were incubated withWR or A35Δ for 5 h and then placed in IL-2-
containing media to stimulate their proliferation. IL-2 increased the
response of the uninfected CTLL compared tomedia containingno IL-2,
and VV did not signiﬁcantly alter this response up to 48 hpi (Fig. 3D).
These data suggest that VV (with or without the A35 gene) has little
effect on either the RsL.11 or CTLL under these assay conditions and
that A35 exerts its inﬂuence directly on the APC instead. In order to
further test this hypothesis, we performed an experiment using a
paraformaldehyde ﬁxed infected human B cell line to present antigen
in triplicate as previously described (Li et al., 2005). WR infected
(MOI=10) ﬁxed B cells presented 30% as well as uninfected ﬁxed B
cells, and signiﬁcantly less than the A35Δ infected ﬁxed B cells, which
presented 68% of the levels of uninfected ﬁxed B cells. These data
mirror what we have seen in the rodent system using unﬁxed antigen
presenting cells where A35 potentiates VV inhibition of antigen
presentation. Together these data indicate that the APC are directly
affected by A35 prior to interaction with T cells. Thus we further
explored the effects of A35 on APC.
A35Δ is as infectious as WR virus
We had previously shown that A35Δ mutant virus particles were
equally infectious on a per particle basis as wild type WR parental
virus (Roper, 2006) in BS-C-1 cells; however, it was possible that the
A35Δ virus infected immune cells (PEC) less well than the wild type,
thus allowing WR to be more inhibitory. In order to assess viral
infectivity in these cells, PEC were incubated with WR and A35Δ for
10 h, and viral antigens were measured by FACS analysis using a
human polyclonal anti-VV hyperimmune serum. In three experi-
ments, the A35Δ showed as much viral antigen staining as wild type
virus (Fig. 4A), indicating that the A35Δ is as infectious as wild typeells. PEC were harvested from Lewis rats, infected with WR or A35Δ virus (MOI=2) for
l line. Supernatants (50 μl) were collected at 24-h post incubation and assayed for the
unoassay Kit. IL-2 and IFNα values were divided by 20 and 100, respectively, to ﬁt to
e in WR, all other differences between WR and A35Δ were pb0.05.
Fig. 3. A35 does not directly affect T lymphocytes. (A) RsL.11 T cells were infected withWR or A35Δ virus (MOI=4) for 4 h and then incubated with decreasing numbers of Ag pulsed
PEC. After 24–48 h, supernatants (50 μl) were collected and assayed for IL-2 production using the CTLL IL-2 bioassay. (B) RsL.11 T lymphocytes were infected for 3–4 h and then
stimulated with PEC/50 nM GPMBP, 25 μg/ml Con A, or 100 nM PMA/2 μM ionomycin. Supernatants (50 μl) were collected at 20- and 40-h and assayed for IL-2. (C) RsL.11 T cells
were infected with VV for 10 h, and growth metabolism was measured by reduction of 10 μl MTS/PMS. (D) CTLL cells were infected with VV (MOI=5) for 4 h and then placed in
media with varying amounts of an IL-2-containing supernatant. Proliferation was measured by adding 10 μl MTS/PMS.
179K.E. Rehm et al. / Virology 397 (2010) 176–186virus in these cells and proceeds normally through viral protein
expression up to 10 hpi. Uninfected cells stained with anti-VV
hyperimmune serum and VV infected cells stained with secondary
antibody alone gave comparable negative results.
A35Δ replicates equal to WR in PECs
We also assessed the replication of both viruses in PEC using a one-
step growth curve. We infected PEC and BS-C-1, a known permissive
cell line, with WR or A35Δ, and harvested supernatants and cells for
titers at various time points. WR and A35Δ were able to replicate
similarly in BS-C-1 cells increasing approximately 2 logs by 30 hpi
(Fig. 4B), while neither virus replicated well in PEC.We alsomeasured
virus released into supernatants (not shown) and showed that WR
and A35Δ had very similar supernatant titers. These data indicate that
A35 does not alter viral replication in PEC.
A35 does not induce apoptosis of PEC
One possible explanation for the A35 mediated reduction in
antigen presentation was that A35 might reduce the viability of the
APC since VV is known to induce apoptosis in many APC types (Broder
et al., 1994; Engelmayer et al., 1999; Humlova et al., 2002;
Kastenmuller et al., 2006). To determine this, PECs were infected
with WR or A35Δ, and metabolism/viability was measured. While
virus infection reduced metabolism/survival of both cell types by 24
hpi, there was no difference in metabolism between the WR- andA35Δ-infected groups, suggesting that A35 does not promote cell
death (Fig. 5A). Similar experiments were carried out in the murine
RAW 264.7 macrophage line, and similar results were obtained: VV
decreased metabolism of RAW, but A35 had no effect. Apoptosis
induction was also measured in PEC using annexin V and propidium
iodide staining at 4, 6 and 28 hpi. VV infection induced apoptosis as
previously reported, from 17% to 43% in Fig. 5B, but A35 had no effect
at any time point measured, indicating that the A35-induced
reduction in antigen presentation was not likely due to the increased
induction of cell death.
A35 does not affect antigen-independent NO production
Since A35 acts on APC and A35 caused an inhibition of NO
production by PEC in antigen presentation assays with T lymphocytes
(Fig. 1), we tested the effects of A35 on NO production in response to
puriﬁed LPS and IFNγ in PEC and the murine RAW 264.7 macrophage
cell line. We infected cells for 4 h with either WR or A35Δ, stimulated
the cells with IFNγ, LPS, or both, and then measured NO production in
supernatants 24 hpi. NO was produced by uninfected PEC and RAW in
response to each stimulus (Fig. 6), and VV infection signiﬁcantly
reduced the amount of NO produced as previously reported (Bellows
et al., 2003); however, the presence of A35 had no effect on this
outcome. We performed this experiment with a higher MOI of 5 and a
lower MOI of 1 to assess whether an A35 effect might be seen at lower
virus infectious dose, but no effect could be detected. Thus, A35 does
not always decrease macrophage NO responses but inhibits NO
Fig. 4. A35Δ mutant virus is as infectious as WR and replicates equally. (A) PEC were
incubated with WR and A35Δ at an MOI of 10 for 10 h, ﬁxed, permeabilized, and
incubated with human polyclonal anti-VV hyperimmune sera. Viral antigens were
measured by ﬂow cytometry. (B) BS-C-1 cells or PEC were infected with either WR or
A35Δmutant virus (MOI=10). Cells were collected at designated times post-infection
and cell-associated virus was measured.
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tions with T cells (Fig. 1). These data suggested that A35 speciﬁcally
blocks the interaction between the PEC and the RsL.11.
A35 and MHC class II and B7.2 expression on APC
Since data suggested that A35 might block interactions between
APC and T cells, we measured the effect of A35 on surface expression
of B7.2/CD86 and MHC class II, proteins important in antigen
presentation. Several laboratories have now shown that VV can
inhibit MHC class II and CD86 expression on APC in vitro and in vivo
under various conditions (Engelmayer et al., 1999; Jenne et al., 2000;
Kastenmuller et al., 2006; Li et al., 2005; Yao et al., 2007). PEC were
infected for 4 h at an MOI of 10 and analyzed by ﬂow cytometry.
Uninfected PECs were 43% bright positive for MHC class II, A35Δ-
infected PECs were 39% and WR-infected PEC were 29% (data not
shown), indicating that the A35 protein plays a role in inhibiting the
highest expression of MHC II on the surface of PECs. We also looked at
how A35 affected the MHC II expression on the 1153 murine B cell
line. Following a similar approach to that described for the PEC,
uninfected 1153 B cells were 38% bright positive (arrow shown) for
MHC II while WR-infected 1153 B cells were 15% (Fig. 7) and A35Δ-
infected cells were 23%, indicating that the presence of A35 in WR
mildly reduced MHC II surface expression. In the same experiments,
there was no difference in CD45 (leukocyte common antigen)
expression between the groups, indicating that VV and the presence
of the A35 gene mildly but speciﬁcally decrease MHC class II on thesurface of APC. CD28 stimulation through B7 is required for protection
from poxvirus infection (Fang and Sigal, 2006), and B7.2 expression
was also measured. PEC and the mouse 1153 B cell line, were infected
at an MOI of 5 for 4 h and incubated with primary antibodies that
recognize B7.2/CD86 costimulatory molecules. Surface expression of
B7.2 costimulatory molecule was decreased from 16% in uninfected
and A35Δ infected cells to 10% in WR infected cells, but infection did
not decrease surface expression of CD45. These data suggest that A35
may modestly downregulate surface proteins required for antigen
presentation.
A35 decreases the amount of peptide presented in MHC II
One level of immune regulation, both in homeostasis and infection,
lies in controlling the association of peptides with the MHCmolecules
that present them (Inaba et al., 2000). We next sought to determine
whether A35 affected the association of peptides with MHC II on the
cell surface. To do this, we used the Y-Ae antibody, which speciﬁcally
detects peptide 52–68 from I-Ed MHC class II bound in the cleft of
mouse MHC class II I-Ab (Itano et al., 2003; Rudensky et al., 1991).
MHC class II molecules frequently present self peptides from surface
proteins that recirculate through endosomes and are degraded,
similar to exogenous antigens that are internalized. The Y-Ae antibody
recognizes a major determinant (approximately 12% of MHC
molecules) in mice expressing both of these class II molecules
(Rudensky et al., 1991; Stimpﬂing and Richardson, 1965). We
measured the amount of peptide bound in the cleft of MHC class II
on the surface of uninfected, WR and A35Δ infected spleen cells. As
Fig. 8 shows, uninfected and A35Δ infected cells were 63% positive for
class II MHC molecules complexed with this I-E peptide, while
infection with WR reduced this to 30% 3 hpi, with only a slight
decrease in MHC class II expression. These data indicate that A35
interferes speciﬁcally with the loading of this model peptide into the
cleft of MHC class II molecules or expression of such molecules on the
cell surface. As surface expression of antigenic peptide was decreased
by A35 in this model system, we tested whetherMHC class II bound to
the remnant chaperone invariant chain peptide CLIP was transported
to the cell surface. CLIP peptide was detectable on approximately 14%
of uninfected cells, 24% of A35Δ infected cells and 33% of WR infected
cells (Fig. 8), suggesting that A35 enhances the binding and/or
transport of CLIP peptides and thusmay interfere with presentation of
a wide variety of naturally occurring MHC class II presented antigenic
peptides.
To determine whether A35 affects VV stimulated immune
responses to VV antigenic peptides during natural infection, we
infected groups of ﬁve mice with 1000 pfu VV i.n. as previously
described (Roper, 2006) and enumerated VV speciﬁc IFN γ secreting
spleen cells on day 8 post infection. WR infected mice produced
signiﬁcantly fewer IFNγ secreting cells compared to A35Δ infected
mice and produced signiﬁcantly lower levels of VV speciﬁc antibody,
suggesting that A35 also acts in vivo to suppress immune responses to
VV (Rehm et al., 2010). PBS-vaccinated mice and vaccinated mouse
cells without virus stimulation were used as negative controls and
produced no signal.
A35 localizes to the endosomes
Since MHC and B7 proteins recycle in endosomes, and MHC class II
is loaded with peptides in the endosomes, we determined the
intracellular localization of A35 in antigen presenting cells. We had
published previously that A35 localizes intracellularly in viral factories
in BS-C-1 ﬁbroblast cells, in which there is no A35 phenotype (Roper,
2006). Since our data suggest that A35 functions in APC early after
infection,we determined the localization of A35 in PECs at a time point
when an A35 phenotype is seen in antigen presentation. PEC were
infected with either WR or A35Δ, and A35 was visualized using
Fig. 6. A35 does not block antigen-independent NO production. PEC (A) or RAW 264.7
macrophages (B) were infected at anMOI of 1 for 4 h andwere stimulated with 2 μl LPS,
2 μl, IFN-γ, or a combination. Supernatants (50 μl) were collected at 24–48 h and then
assayed for NO production.
Fig. 5. PEC (A) were infected with A35Δ or VVWR (MOI=2) andmetabolismwasmeasured by the reduction of 10 µl MTS/PMS. PEC apoptosis (B) wasmeasured using annexin V and
propidium iodide and ﬂow cytometry following a 4-h infection.
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could be seen as diffuse punctuate staining throughout the cell (Fig. 9),
which is consistent with the staining of endosomal structures, where
many aspects of MHC II antigen processing and presentation occur. In
order to verify endosomal localization,we co-localized theA35protein
with known endosomal markers, Rab 5 (plasma membrane and early
endosomes), Rho B (multivesicular bodies), Rab 7 (late endosomes),
and Lamp-1 (late endosomes and lysosomes) (Chavrier et al., 1990;
Feng et al., 1995; Lippincott-Schwartz and Fambrough, 1987)
(Robertson et al., 1995). A35 showed partial co-localization with
these endosomal markers, although least with Rab5 (Fig. 9). In each
case there were endosomal structures that had both A35 and the
marker (yellow colocalization) but also punctate staining for each
antibody alone (green or red). Thus, A35 localizes generally through-
out the range of endosomes in the cell but is not found in all
endosomes and does not partition to any distinct endosomal type. The
presence of A35 in these structures suggests that A35 protein may
interact with or affect proteins in endosomes including class II MHC,
although further research is required to elucidate with which proteins
A35 interacts speciﬁcally.
Discussion
We showed previously that the VV A35 gene is an important
virulence factor, increasing virulence by 100–1000 fold (Roper, 2006,
Rehm et al., 2010), but its function was unknown. We have shown
here that the VV A35 gene product is not required for replication in a
variety of cell types and tissues in six different mammals. Further-
more, A35 does not control early replication in mouse tissues on days
Fig. 7. A35 decreases MHC class II expression. 1153 B cells were infected with WR or A35Δ virus for 5 h, washed and incubated with no primary antibody, anti-class II MHC, or anti-
CD45 and then FITC-conjugated secondary and analyzed by ﬂow cytometry. Mean ﬂuorescence intensities (MFI) for MHC class II were Un 154, A35Δ 111, and WR 77.
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have shown that A35 affects the development of adaptive immune
responses in vitro, speciﬁcally acting on APC. A35 contributes to VV-
induced reduction in MHC II antigen presentation (Fig. 1) and
subsequent cytokine synthesis (Fig. 2) using primary macrophages
as APC, even though the mutant virus was able to infect the APC as
efﬁciently as wild type (Fig. 4). A35 did not affect metabolism,
permissiveness, apoptosis of PEC nor NO production induced by
immunostimulators in rat PEC or the murine RAW macrophage cell
line. These data suggested that A35 did not have a major systemic
effect on macrophage but rather that it speciﬁcally interfered with the
interaction between APC and T cells since those assays speciﬁcally
showed an A35-dependent phenotype.
We subsequently found that A35 mildly affected the expression of
MHC class II on the surface of the APC (Fig. 8). While several
laboratories have now shown that VV can inhibit MHC class II and
CD86 expression on APC in vitro and in vivo under various conditions,
there has been much debate about the circumstances under which
this regulation occurs and its signiﬁcance (Li et al., 2005). Some
laboratories have associated the reduction in surface molecules with
induction of apoptosis (Kastenmuller et al., 2006), while others have
concluded that VV does not block basal B7.2 or class II MHC expression
but that it blocks activation-induced B7.2 or class II MHC expression
(Engelmayer et al., 1999, Jenne et al., 2000). We have found that early
after infection, VV and the A35 gene canmildly decrease expression of
these surface markers both in rat PEC and in a murine B cell line.
Whether a small decrease in MHC class II levels will have physiologicFig. 8. A35 decreases the amount of antigenic peptide associated with MHC class II. Splenocy
an MOI=10, washed, and then incubated with no primary antibody, antibodies to MHC
streptavidin-RPE. Samples were analyzed by ﬂow cytometry, and MFI for Y-Ae were Un 85signiﬁcance is unknown; however it is known that MHC class II
antigen presentation is crucial to protection from poxvirus infection.
In studies with knockout mice, it was found that the absence of MHC
class I molecules or CD8 T cell response did not diminish protection
but that decreases in CD4 or MHC class II expression caused a loss of
protective immunity (Wyatt et al., 2004; Xu et al., 2004).
VV genes B1R and H5R have been shown to inhibit CD1d mediated
non-classical lipid antigen presentation, although the importance of
this function was difﬁcult to ascertain because of the pleiotropic
effects of these genes (Webb et al., 2006). Several laboratories have
shown that VV also blocks MHC class II antigen presentation in a
number of assays using different APC, model antigens (exogenous,
virus encoded and cellular endogenous) and response measures
(Rehm et al., 2009). VV-infected primary Langerhans cells were
deﬁcient in presenting KLH peptide to a cognate T cell line, as
measured by production of IFNγ (Deng et al., 2006). Primary rodent
bonemarrow derivedmacrophages infectedwith VVwere deﬁcient in
presenting lysozyme peptide to T cells, as measured by stimulation of
IL-2 production (Mann et al., 2008). Li et al. found that VV inhibited
MHC class II antigen presentation in in vitro infected human and
rodent APC, including B cell lines, dendritic cells, macrophage and
ﬁbroblasts presenting several antigens (Li et al., 2005). The accumu-
lation of data indicates that VV generally inhibits MHC class II antigen
presentation; however, no viral gene had previously been identiﬁed
as blocking antigen presentation. We have shown here that A35
interferes with antigen presentation responses to an exogenous
model antigen (Figs. 1 and 2), as well as surface expression of antes from B10.A-H2^i5 H2-T18^a/(5R)SgSnJ mice (Jackson Labs) were infected for 3 h at
class II or CLIP, or biotin-conjugated Y-Ae anti peptide in MHC antibody followed by
, A35Δ 76, and WR 36. MFI for CLIP were Un 5.7, A35 Δ 8.2, and WR 13.9.
Fig. 9. A35 localization in PEC. PEC were grown on coverslips for 4 h and then infected
with WR or A35Δ virus at an MOI=10 for 2 h. The cells were then ﬁxed and
permeabilized and stained with a rabbit anti-A35 antibody and one of the following:
goat anti-LAMP, goat anti-Rab5, goat anti-RhoB, goat anti-Rab7. The A35 protein was
visualized with a FITC-conjugated secondary antibody, and the endosomal markers
were visualized with Alexa Fluor 633.
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A35 increases surface CLIP expression in MHC class II suggesting that
A35 may inhibit presentation of a range of antigenic peptides.
Furthermore, we have found that A35 diminishes anti-VV T cell
responses and antibody in mice (Rehm et al., 2010), suggesting that
A35 may similarly inhibit presentation of virally expressed VV
antigens during infection in vivo.
Our data suggest that VV A35 contributes to viral inhibition ofMHC
class II antigen presentation by decreasing the expression of antigenic
peptides in the cleft of MHC class II on the surface of infected cells. We
showed this in themurine systemwith anMHC derived peptide as the
antigen. Dr. Blum's laboratory showed that VV decreases the amount
of GAD peptide in the cleft of MHC class II in a human B cell line (Li
et al., 2005). Together these data suggest that VV inhibition of peptide
loading into the cleft is a general mechanism of immune response
inhibition independent of the antigen or APC type. The fact that A35 is
very highly conserved in mammalian tropic poxviruses suggests that
A35 may act similarly in a number of different viruses and host
species. Interestingly, Fig. 8 shows that there is a population of cells inspleens that is unaffected by the presence of VV and A35 gene (MOI of
10). Since splenocytes contain numerous cell types, these data suggest
that there is a VV resistant population in the spleen, consistent with
other studies showing differing sensitivities to infection among
immune cells (Chahroudi et al., 2005; Sanchez-Puig et al., 2004). It
will also be important to determine the effects of A35 on lymphocytes
in the target organs, especially the lungs.
In these experiments, we showed that A35 inhibited antigen
presentation, suggesting that the A35Δ mutant viruses will provide
improved vaccines, as well as improved platform vaccines for other
infectious diseases and cancer treatment. The A35 gene is conserved
in all VV vaccine strains including MVA. While A35 inhibited antigen
presentation, it was also clear that the A35 deletion mutant virus
blocked antigen presentation when compared to uninfected APC
(Figs. 1 and 2). This suggests that there are multiple poxvirus proteins
that function independently to decrease antigen presentation. It is
important to identify these immunosuppressive genes and test the
cognate knockout viruses as improved poxvirus (or poxvirus
platform) vaccines.
While we showed that both T cell and PEC cytokine production
was reduced subsequent to antigen presentation interactions, our
data indicated that it was the APC that were directly affected by VV,
and the T cells were indirectly affected via regulation of the APC. A35
had the effect of suppressing the production of numerous cytokines
and chemokines, which are crucial in the development of an
appropriate immune response. Notably, many of the cytokines that
are regulated by VV and A35 are chemotactic factors (MIP-1α, IL-1,
TNF-α, GRO/KC, RANTES, and MCP-1), which aid in the migration of
immune response cells to sites of inﬂammation and infection.
Interestingly, IL-18 was not signiﬁcantly reduced by VV and A35
(Fig. 2). Perhaps this is because IL-18 is stored intracellularly as pro-
IL-18 and rapidly released upon stimulation (Gardella et al., 2000).
Since IL-18 is an important factor in the induction of anti-viral IFNγ
production, its storage for rapid release may be an evolved host
mechanism to contravene immunomodulation by viral gene products
such as A35. The importance of IL-18 in antiviral defense is under-
scored by the possession of an IL-18 binding protein encoded by
poxviruses (Reading and Smith, 2003).
There are multiple mechanisms by which A35 could decrease MHC
II peptide presentation that must be further explored. Future
experiments will address with which cellular proteins A35 interacts.
Since A35 may affect peptide loading, it is possible that it interacts
with invariant chain that chaperones MHC class II proteins, directly
with MHC class II itself, or DM molecules that are involved in the
exchange of antigenic peptides. Furthermore, we will test various
immune responses to the A35Δ mutant virus in comparison to wild
type virus in transgenicmousemodels to understandwhich pathways
are inhibited by A35. Our hypothesis is that A35 acts through blocking
MHC class II antigen presentation, and we predict that anti-viral CD4
responses will be diminished and that this decrease in T helper cells
will diminish development of most downstream anti-viral effector
cells (including CD8 cytotoxic T cells and antibody secreting B cells).
Thus far our animal model data are consistent with this hypothesis,
showing a reduction in both VV speciﬁc antibody and splenic T
lymphocyte responses (Rehm et al., 2010).
Materials and methods
Cells and virus
VV Western Reserve (WR) strain and A35Δ mutant virus stocks
were propagated using BS-C-1 cells as previously described (Roper,
2006). For titrations of VV, BS-C-1 monolayers were ﬁxed and stained
with 0.1% crystal violet in 20% ethanol. All cells were grown in media
containing 10% fetal bovine serum. CD4+ RsL-11 T cell clones were
derived and maintained as previously described (Mannie and Norris,
184 K.E. Rehm et al. / Virology 397 (2010) 176–1862001). CTLL-2 (ATCC #TIB-214) were maintained in RPMI supple-
mented with 0.4% IL-2-containing baculovirus supernatant (Mannie
and Norris, 2001). RAW 264.7 (ATCC #TIB-71), a mouse macrophage
cell line, was maintained in DMEM. The mouse B cell line 1153 (kind
gift from Janice Blum) was maintained in RPMI (Li et al., 2005).
Cell tropism replication
The cell type of interest was split into two groups of equal number
for infection. One group was infected with WR and the other with
A35Δ. The cells were infected for 20 h at MOI=1 followed by three
freeze/thaw cycles to release newly formed virus particles. Replica-
tion was measured by titering the cell lysates on a monolayer of BS-C-
1 cells and counting the plaques that formed 40 h later. For early
replication in mouse organs, groups of mice were intranasally
challenged with WR (Roper, 2006) and A35Δ at 104 pfu/mouse, and
nose, lungs, blood, brain and spleen were harvested on days 1, 2 and 3
(six mice on each day) post challenge. Organs were freeze/thawed
three times, homogenized, sonicated, and titered as above.
Peritoneal macrophage isolation and antigen presentation assays
Lewis rats (bred and maintained at the AAALAC-certiﬁed Brody
School of Medicine animal care facility at East Carolina University)
were injected intraperitoneally with 200 μg of inactivated C. parvum
in 5 ml of HBSS. Two to three days later, the rats were sacriﬁced and
peritoneal exudate cells (PEC) were harvested by washing the
peritoneum in cold HBSS. PEC (N95% CD45+ hematopoietic lineage)
infected for 5 h with either WR or A35Δ and placed into 96-well
plates. PEC were incubated with 50 nM guinea pig myelin basic
protein (GPMBP) for 30 min, followed by addition of 25,000 Lewis rat
CD4+ RsL.11 clones speciﬁc for GPMBP (Mannie and Norris, 2001).
The antigen presentation plates were incubated for 24–48 h at 37 °C,
5.0% CO2. After incubation, 50 μl of supernatants were transferred into
an empty 96-well plate and frozen for the following assays. All animal
experiments were in compliance with NIH guidelines.
CTLL IL-2 bioassay
IL-2 was measured using previously described methods (Mannie
and Norris, 2001). Brieﬂy, 10,000 CTLL clones were washed,
resuspended in RPMI, and added to the collected supernatants. The
plates were incubated for 48 h at 37 °C, 5.0% CO2, followed by the
addition of 10 μl of MTS/PMS (2.0 mg/mL MTS, Promega and 0.1 mg/
mL PMS, Sigma). The absorbance was read at 492 nm. Media only was
used to deﬁne the background control level and known IL-2 contain-
ing supernatants were used as positive control.
NO measurement
50 μl of the harvested supernatants were transferred into a
separate 96-well plate followed by the addition of 50 μl of Griess
Reagent (1% sulfanilamide–0.1% N-[1-naphthy] ethylenediamine in
2.5% phosphoric acid) into each well. The absorbance was read at
540 nm (Campos-Neto et al., 1998).
Cytokine measurement
50 μl of the harvested supernatants were analyzed using the
LincoPlex 24 Rat Cytokine/Chemokine Luminex Bead Immunoassay
Kit according to the manufacturer's instructions (Linco Research). The
supernatants were incubated with a panel of anti-cytokine Abs
immobilized on Luminex beads (Bio-Rad Laboratories). The following
cytokines were analyzed: IL-1α, IL-1β, IL-2, IL-6, IL-17, IL-18, MIP-1α,
GM-CSF, IFN-α, growth regulated oncogene alpha/keratinocyte
attractant (GRO/KC), RANTES, TNF- α, MCP-1, eotaxin, G-CSF, IL-4,IL-9, IL-13, IL-5, and IL-10. Reagents for IFNγwere not available at the
time. Samples were run according to the manufacturer's instructions
(Bio-Rad) and analyzed on the BioPlex protein array reader (Bio-Rad)
in the Duke University Human Vaccine Institute Immune Reconstitu-
tion Core Facility (Durham, NC).
RsL-11 stimulation assay
CD4+ RsL.11 T lymphocytes were washed and resuspended in
RPMI. The cells were infected for 3–4 h, plated in a 96-well format, and
stimulated with PEC pulsed with 50 nM GPMBP, 25 μg/ml Con A
(Sigma), or 100 nM PMA/2 μM ionomycin (Sigma). The plates were
incubated at 37°, 5% CO2. 50 μl of the harvested supernatants were
collected at 20- and 40-h and assayed for IL-2 using the CTLL bioassay
already described.
Metabolism/survival assays
Cells of interest were infected with VV (MOI=2). Metabolism was
measured by the addition of 10 μl MTS/PMS 4-24 hpi and analyzed
similarly to the method described above for the CTLL IL-2 Bioassay.
Absorbance was read at 492 nm at various times post infection.
Tetrazolium salts such as MTS are reduced to colored formazan
products during cellular respiration. As only live cells respire, the MTS
assay can be used to measure cell survival.
Flow cytometry
Cells were infected for 4 h and then washed in cold PBS containing
1% heat-inactivated FBS and 0.1% sodium azide. 3×105 cells were
stained with an anti-MHC II concentrated supernatant (Y3P, AF6120,
and MKS4), OX1 anti-CD45, or human anti-VV (Cangene VIG) for 1 h
on ice, washed once, and then incubated with a FITC-conjugated goat
anti-mouse IgG (Southern Biotech) or anti-human-PE. For measure-
ment of apoptosis, cells were infected and then stained with
annexinV-FITC/propidium iodide (PI) (BD Pharmingen) per the
manufacturer's instructions. Expression was measured using a
FACScan (Becton Dickinson) and analyzed with Cell Quest software.
Peptide–MHC association
The Y-Ae antibody speciﬁcally detects a complex of peptide 52–68
from I-Ed MHC class II bound in the cleft of MHC class II I-Ab (Itano et
al., 2003; Rudensky et al., 1991). This complex is formed in mice that
express both alleles. Spleens were harvested from B10.A-H2^i5 H2-
T18^a/(5R)SgSnJ mice (Jackson Labs); C57Bl/6 mice were used as a
negative control. Unfractionated splenocytes were infected with
sucrose gradient puriﬁed virus for 3 h (MOI=10) and then incubated
with biotin-conjugated Y-Ae (eBioscience). Cells were washed and
incubated with streptavidin-RPE (Southern Biotech). Goat polyclonal
IgG antibody to CLIP (P-15, Santa Cruz) and donkey anti-goat IgG FITC
(Jackson Labs) were used tomeasure CLIP peptide bound inMHC class
II on the surface of cells. Samples were analyzed using a FACScan
equipped with Cell Quest software.
Immunoﬂuorescence microscopy
PEC were harvested as described above and grown on coverslips
for 4 h. The cells were then infected at an MOI=10 for 2 h, ﬁxed and
permeabilized in 3% paraformadehyde and 0.1% Triton X-100,
respectively, and then stained with a rabbit anti-A35 antibody
1:4000 (Roper, 2006) and one of the following polyclonal goat anti-
endosome antibodies (Santa Cruz Biotechnology) at 1:80 diluted in
0.1% Triton X-100/PBS: Lamp-1 (C-20), Rab 7 (A-16), Rab 5B (C-12),
or RhoB (M-19). The coverslips were then washed and incubated with
Alexa Fluor 633 (Invitrogen) and a FITC-conjugated anti-rabbit IgG
185K.E. Rehm et al. / Virology 397 (2010) 176–186(Sigma) for 45 m, followed by a ﬁnal round of washes. The cells were
visualized with a Zeiss confocal microscope and pictures were taken
with the 100 objective.
One-step growth curve
A one-step growth curve was performed as previously described
(Roper, 2006).
IFNγ elispot
To enumerate cells secreting IFNγ, 96-well ELISA plates (Immulon
H2B Thermo Electron) were coated overnight with rat anti-mouse
IFN-γ (1 mg/ml Pharmingen). Plates were washed with blocking
buffer (PBS 1% FBS) before adding murine splenocytes in RPMI 1640.
Stimulation of splenocytes was achieved by the addition of virus
(MOI=2) followed by incubation for 40 h at 37 °C. Plates were then
washed and incubated with 0.4 μl biotinylated rat anti-mouse IFN- γ
(Pharmingen 0.5 mg/ml). Plates were washed and incubated with
streptavidin AP for 1 h at 37 °C. Plates were developed with agarose/
BCIP/AMP buffer mixture. Spots were counted using a dissection
microscope.
Statistical analysis
Experiments were repeated at least three times and representative
data are shown. A two-tailed Student's t test was used to compare
groups. p values b0.05 were considered signiﬁcant.
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